Pharmacodynamic Evaluation of TEV-56192 in a Double-Blind, Randomized, Placebo-Controlled Phase 1b Trial for Pruritus in Healthy Subjects

The primary objective of this study is to evaluate the **pharmacodynamic** effects of TEV-56192 following a single intravenous administration in healthy participants. This is a double-blind, randomized, placebo-controlled, Phase 1b trial. The clinical relevance of this study lies in its potential to provide insights into the treatment of **pruritus**, a condition characterized by severe itching, which can significantly impact quality of life. Understanding the pharmacodynamics of TEV-56192 may contribute to the development of effective therapeutic strategies for managing pruritus.

The clinical trial focuses on **pruritus** and includes a study population comprising both male and female participants. The age range of the participants spans from adolescents to adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria have not been specified, and the general health status of the participants is not detailed in the available data.

The clinical trial is designed as a **double-blind**, **randomized**, **placebo-controlled** study, focusing on the pharmacodynamic effects of TEV-56192 following a single intravenous administration in healthy participants. The trial is categorized as a Phase 1b study and aims to investigate the effects of the investigational product on **pruritus**. The estimated recruitment start date is February 1, 2024, with an anticipated end date of July 31, 2024, indicating a total trial duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for trial inclusion. Following successful screening, participants will be randomly assigned to receive either the investigational product or a placebo, maintaining the double-blind nature of the study to ensure unbiased results.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the pharmacodynamic effects of the treatment. These visits are crucial for collecting data on the safety and efficacy of the investigational product. The trial will conclude with an end-of-study visit, where final assessments will be conducted to gather comprehensive data on the participants' responses to the treatment.

The expected length of participant involvement is approximately six months, aligning with the overall trial duration. However, certain conditions may lead to early termination from the study, such as adverse reactions to the investigational product, non-compliance with study protocols, or withdrawal of consent by the participant. These measures ensure the safety and integrity of the trial while maintaining adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 1, 2024, with an estimated completion date of July 31, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design will likely incorporate validated scales, laboratory tests, or patient-reported outcomes to measure efficacy, consistent with standard practices in clinical research. The results will contribute to understanding the treatment's potential benefits and inform future clinical and regulatory decisions.